P-glycoprotein (P-gp) affects the pharmacodynamics of the atypical antipsychotic amisulpride

被引：0
|
作者：
Schmitt, U [1 ]
Härtter, S [1 ]
Hiemke, C [1 ]
机构：
[1] Univ Mainz, D-6500 Mainz, Germany
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2004年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [1] P-glycoprotein (P-gp) affects the pharmacodynamics and of the atypical antipsychotic amisulpride
    Schmitt, U
    Hiemke, C
    Härtter, S
    PHARMACOPSYCHIATRY, 2003, 36 (05) : 262 - 262
  • [2] Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)
    Schmitt, U.
    Abou El-Ela, A.
    Guo, L. J.
    Glavinas, H.
    Krajcsi, P.
    Baron, J. M.
    Tillmann, C.
    Hiemke, C.
    Langguth, P.
    Haertter, S.
    JOURNAL OF NEURAL TRANSMISSION, 2006, 113 (07) : 787 - 801
  • [3] Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)
    U. Schmitt
    A. Abou El-Ela
    L. J. Guo
    H. Glavinas
    P. Krajcsi
    J. M. Baron
    C. Tillmann
    C. Hiemke
    P. Langguth
    S. Härtter
    Journal of Neural Transmission, 2006, 113 : 787 - 801
  • [4] IS INHIBITION OF P-GLYCOPROTEIN (P-GP) SUBSTRATE DEPENDENT?
    Louie, Steven W.
    Hsiao, Peng
    Unadkat, Jashvant D.
    DRUG METABOLISM REVIEWS, 2014, 45 : 252 - 253
  • [5] DETECTION AND LOCALIZATION OF P-GLYCOPROTEIN (P-GP) IN THE KIDNEY
    TOBE, S
    LIEBERMAN, D
    GOLDBERG, H
    SKORECKI, K
    REITHMEIER, R
    KIDNEY INTERNATIONAL, 1990, 37 (01) : 234 - 234
  • [6] CHOLESTATIC STEROID GLUCURONIDES - INTERACTIONS WITH P-GLYCOPROTEIN (P-GP)
    VORE, M
    GOSLAND, M
    TSUBOI, C
    HOFFMAN, T
    HEPATOLOGY, 1993, 18 (04) : A139 - A139
  • [7] Vitamin E formulation affects digoxin absorption by inhibiting P-glycoprotein (P-gp) in humans.
    Chan, L
    Humma, LM
    Schriever, CA
    Fahsingbauer, LA
    Dominguez, CP
    Baum, CL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P95 - P95
  • [8] Effects of P-glycoprotein (P-GP) inhibitors on CYP3A.
    Wandel, C
    Kim, RB
    Kajiji, S
    Guengerich, FP
    Wood, AJJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 206 - 206
  • [9] RELUGOLIX ORAL BIOAVAILABILITY IS DRIVEN PREDOMINANTLY BY P-GLYCOPROTEIN (P-GP).
    Buckley, D.
    Migoya, E.
    Lee, T.
    Ferreira, J. Arjona
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S43 - S43
  • [10] Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition
    Dewanjee, Saikat
    Dua, Tarun K.
    Bhattacharjee, Niloy
    Das, Anup
    Gangopadhyay, Moumita
    Khanra, Ritu
    Joardar, Swarnalata
    Riaz, Muhammad
    De Feo, Vincenzo
    Zia-Ul-Haq, Muhammad
    MOLECULES, 2017, 22 (06)
12345